Base de dados : MEDLINE
Pesquisa : C05.116.198.579 [Categoria DeCS]
Referências encontradas : 38262 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 3827 ir para página                         

  1 / 38262 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29200854
[Au] Autor:Qu Y; Wang Z; Zhou H; Kang M; Dong R; Zhao J
[Ad] Endereço:Department of Orthopedics, The Second Hospital of Jilin University, Changchun, People's Republic of China.
[Ti] Título:Oligosaccharide nanomedicine of alginate sodium improves therapeutic results of posterior lumbar interbody fusion with cages for degenerative lumbar disease in osteoporosis patients by downregulating serum miR-155.
[So] Source:Int J Nanomedicine;12:8459-8469, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Degenerative lumbar disease (DLD) is a significant issue for public health. Posterior lumbar intervertebral fusion with cages (PLIFC) has high-level fusion rate and realignment on DLD. However, there are some complications following the surgery. Alginate oligosaccharides (AOS) have antioxidant and anti-inflammatory activities and may be suitable for infection therapy. MiR-155 is a biomarker associated with inflammatory and oxidative stress. AOS may promote PLIFC therapy by regulating miR-155. Pluronic nanoparticles and oligosaccharide nanomedicine of alginate sodium (ONAS) were prepared with ampicillin at size <200 nm. Ninety-six DLD osteoporosis patients received PLIFC and were evenly assigned into ONAS group (OG, oral administration of 100 mg ONAS daily) and control group (PG, 100 mg pluronic nanoparticles). Serum miR-155 level was measured by real-time quantitative PCR. The levels of superoxide dismutase (SOD), glutathione (GSH), aspartate aminotransaminase (AST), alanine aminotransferase (ALT), interleukin-1ß (IL-1ß), and interleukin-1 receptor antagonist (IL-1ra) were measured. Weighted mean difference (WMD), relative risk (RR), complications, surgery infection rate, fusion rate, and Japanese Orthopaedic Association (JOA) scores were used to evaluate therapeutic efficacy. After 1-month therapy, infection rates and side effects were lower in OG than those in PG (RR =0.64, 95% confidence interval [CI] [0.48, 0.84], =0.001). The fusion rates were higher in OG than in PG (WMD =21.96, 95% CI [-0.24, 37.62], =0.021). The JOA scores were higher in OG than in PG (RR =0.52, 95% CI [0.33, 0.84], =0.007), and no significant difference was found for the visual analog scale and Oswestry Disability Index. Serum levels of miR-155, ALT, AST, and IL-1ß were lower while SOD, GSH, and IL-1ra were higher in OG than in PG. MiR-155 mimic increased the levels of ALT, AST, and IL-1ß and reduced the levels of SOD, GSH, and IL-1ra. In contrast, miR-155 inhibitor had reverse results. Therefore, ONAS has better improvement in complications and therapeutic effects on DLD by regulating serum miR-155.
[Mh] Termos MeSH primário: Alginatos/farmacologia
Degeneração do Disco Intervertebral/terapia
Vértebras Lombares/patologia
MicroRNAs/sangue
Nanomedicina/métodos
Oligossacarídeos/farmacologia
Osteoporose/complicações
Fusão Vertebral
[Mh] Termos MeSH secundário: Idoso
Antioxidantes/farmacologia
Linhagem Celular Tumoral
Citocinas/metabolismo
Regulação para Baixo/efeitos dos fármacos
Regulação para Baixo/genética
Feminino
Ácido Glucurônico/farmacologia
Ácidos Hexurônicos/farmacologia
Seres Humanos
Degeneração do Disco Intervertebral/sangue
Degeneração do Disco Intervertebral/genética
Masculino
MicroRNAs/genética
Nanopartículas/ultraestrutura
Estresse Oxidativo/efeitos dos fármacos
Garantia da Qualidade dos Cuidados de Saúde
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alginates); 0 (Antioxidants); 0 (Cytokines); 0 (Hexuronic Acids); 0 (MIRN155 microRNA, human); 0 (MicroRNAs); 0 (Oligosaccharides); 8A5D83Q4RW (Glucuronic Acid); 8C3Z4148WZ (alginic acid)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171205
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S143824


  2 / 38262 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29429184
[Au] Autor:Gu CY; Han WW; Wu YQ; Fan ZY; Chen CJ; Chen HM
[Ad] Endereço:Department of Neurology, Ningbo No.2 Hospital, Ningbo 315010, China.
[Ti] Título:[Study on bone metabolism in postmenopausal women with idiopathic benign paroxysmal positional vertigo].
[So] Source:Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi;53(2):134-137, 2018 Feb 07.
[Is] ISSN:1673-0860
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To analyze the bone mineral density and serum osteocalcin levels in postmenopausal women with idiopathic benign paroxysmal positional vertigo. A total of 64 postmenopausal women with idiopathic BPPV were selected as the study group, and 98 postmenopausal healthy women were selected as the control group. Bone mineral density and serum osteocalcin levels were analyzed and compared between the groups.χ(2) test was used for numeration data and test was used for measurement data. The prevalence of osteoporosis or osteopenia in BPPV group 67.2% (43/64) was significantly higher than that in the control group 51.0% (50/98) (χ(2)=4.139, =0.042). Among BPPV subjects, there was a negative correlation between osteocalcin and bone density T ( =-0.469, <0.001). Osteocalcin was found in normal bone mass subgroup (13.61±4.32)µg/L, decreased bone mass subgroup (17.49±7.61)µg/L, and osteoporosis subgroup (20.83±6.72)µg/L, respectively, and the difference was statistically significant ( =5.39, =0.007). Bone mineral density in BPPV group is lower than that in control group. The lower the bone mineral density of the patients, the higher the osteocalcin in BPPV group.
[Mh] Termos MeSH primário: Vertigem Posicional Paroxística Benigna/sangue
Densidade Óssea
Osteocalcina/sangue
Pós-Menopausa/sangue
[Mh] Termos MeSH secundário: Estudos de Casos e Controles
Feminino
Seres Humanos
Osteoporose/epidemiologia
Prevalência
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
104982-03-8 (Osteocalcin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180213
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.1673-0860.2018.02.010


  3 / 38262 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453635
[Au] Autor:Balasuriya CND; Evensen KAI; Mosti MP; Brubakk AM; Jacobsen GW; Indredavik MS; Schei B; Stunes AK; Syversen U
[Ad] Endereço:Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, 7489 Trondheim, Norway.
[Ti] Título:Peak Bone Mass and Bone Microarchitecture in Adults Born With Low Birth Weight Preterm or at Term: A Cohort Study.
[So] Source:J Clin Endocrinol Metab;102(7):2491-2500, 2017 Jul 01.
[Is] ISSN:1945-7197
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Context and Objectives: Peak bone mass (PBM) is regarded as the most important determinant of osteoporosis. Growing evidence suggests a role of intrauterine programming in skeletal development. We examined PBM and trabecular bone score (TBS) in adults born preterm with very low birth weight (VLBW) or small for gestational age (SGA) at term compared with term-born controls. Design, Setting, Participants, and Outcomes: This follow-up cohort study included 186 men and women (25 to 28 years); 52 preterm VLBW (≤1500 g), 59 term-born SGA (<10th percentile), and 75 controls (>10th percentile). Main outcome was bone mineral density (BMD) by dual x-ray absorptiometry. Secondary outcomes were bone mineral content (BMC), TBS, and serum bone markers. Results: VLBW adults had lower BMC and BMD vs controls, also when adjusted for height, weight, and potential confounders, with the following BMD Z-score differences: femoral neck, 0.6 standard deviation (SD) (P = 0.003); total hip, 0.4 SD (P = 0.01); whole body, 0.5 SD (P = 0.007); and lumbar spine, 0.3 SD (P = 0.213). The SGA group displayed lower spine BMC and whole-body BMD Z-scores, but not after adjustment. Adjusted odds ratios for osteopenia/osteoporosis were 2.4 and 2.0 in VLBW and SGA adults, respectively. TBS did not differ between groups, but it was lower in men than in women. Serum Dickkopf-1 was higher in VLBW subjects vs controls; however, it was not significant after adjustment for multiple comparisons. Conclusions: Both low-birth-weight groups displayed lower PBM and higher frequency of osteopenia/osteoporosis, implying increased future fracture risk. The most pronounced bone deficit was seen in VLBW adults.
[Mh] Termos MeSH primário: Densidade Óssea/fisiologia
Desenvolvimento Ósseo/fisiologia
Matriz Óssea/fisiologia
Recém-Nascido Pequeno para a Idade Gestacional/crescimento & desenvolvimento
Recém-Nascido de muito Baixo Peso
Nascimento a Termo
[Mh] Termos MeSH secundário: Absorciometria de Fóton/métodos
Adulto
Fatores Etários
Estudos de Coortes
Intervalos de Confiança
Feminino
Fraturas Espontâneas/epidemiologia
Fraturas Espontâneas/fisiopatologia
Seres Humanos
Recém-Nascido
Modelos Logísticos
Masculino
Razão de Chances
Osteoporose/epidemiologia
Osteoporose/fisiopatologia
Fatores Sexuais
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1210/jc.2016-3827


  4 / 38262 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29403337
[Au] Autor:Umunakwe OC; Herren D; Kim SJ; Kohanim S
[Ad] Endereço:Department of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, Tennessee.
[Ti] Título:Diffuse ocular and orbital inflammation after zoledronate infusion-case report and review of the literature.
[So] Source:Digit J Ophthalmol;23(4):18-21, 2017.
[Is] ISSN:1542-8958
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bisphosphonates have become a commonly used class of medications to treat osteoporosis and other bone diseases. Zoledronate (zoledronic acid) can be dosed annually via intravenous infusion, making it an appealing option for patients and physicians. We report the case of a 68-year-old woman who developed severe, unilateral, ocular inflammation, including corneal endotheliitis, anterior uveitis with hyphema, scleritis, and orbital inflammation beginning 12 hours after receiving her first zoledronate infusion. Symptoms escalated but ultimately resolved with topical steroids and high-dose systemic corticosteroids. To our knowledge, this is the first report of unilateral diffuse inflammation of the eye and orbit, including corneal inflammation developing within 12 hours of a first zoledronate infusion.
[Mh] Termos MeSH primário: Difosfonatos/efeitos adversos
Imidazóis/efeitos adversos
Doenças Orbitárias/induzido quimicamente
Osteoporose/tratamento farmacológico
Uveíte Anterior/induzido quimicamente
[Mh] Termos MeSH secundário: Doença Aguda
Idoso
Conservadores da Densidade Óssea/administração & dosagem
Conservadores da Densidade Óssea/efeitos adversos
Difosfonatos/administração & dosagem
Feminino
Seres Humanos
Imidazóis/administração & dosagem
Inflamação/induzido quimicamente
Inflamação/diagnóstico
Infusões Intravenosas
Doenças Orbitárias/diagnóstico
Tomografia Computadorizada por Raios X
Uveíte Anterior/diagnóstico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Bone Density Conservation Agents); 0 (Diphosphonates); 0 (Imidazoles); 6XC1PAD3KF (zoledronic acid)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180207
[St] Status:MEDLINE
[do] DOI:10.5693/djo.02.2017.08.002


  5 / 38262 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28458336
[Au] Autor:Nakamura Y; Suzuki T; Kamimura M; Ikegami S; Uchiyama S; Kato H
[Ad] Endereço:Department of Orthopaedic Surgery, Shinshu University School of Medicine.
[Ti] Título:Alfacalcidol Increases the Therapeutic Efficacy of Ibandronate on Bone Mineral Density in Japanese Women with Primary Osteoporosis.
[So] Source:Tohoku J Exp Med;241(4):319-326, 2017 04.
[Is] ISSN:1349-3329
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Bisphosphonates (BPs) increase bone mineral density (BMD) through the inhibition of osteoclast activity. Among BPs, ibandronate (IBN) is a strong inhibitor of bone resorption. However, the effects of a vitamin D analogue, alfacalcidol (ALF), on IBN treatment for osteoporosis is unknown. Fifty-three treatment-naïve post-menopausal women with primary osteoporosis were recruited and divided into IBN-treatment group (IBN group) and IBN with ALF group (IBN/ALF group). IBN (1.0 mg) was intravenously injected once a month, with or without oral ALF (1.0 µg/day). Ultimately, 19 subjects in IBN group and 26 in IBN/ALF group were analyzed. Bone turnover markers were examined at 4, 6, 12, and 18 months, and BMD was measured at 6, 12, and 18 months. Compared with pre-treatment, bone turnover markers significantly decreased in both groups after 4 months. The levels of serum N-terminal propeptide of type-1 procollagen and tartrate-resistant acid phosphatase-5b, and urinary N-terminal telopeptide of type-I collagen were significantly lower in IBN/ALF group than those in IBN group at 12 months. Lumbar 1-4 (L)-BMD significantly increased from 6 months in IBN/ALF group and at 18 months in IBN group. L-BMD was significantly higher in IBN/ALF group (6.6% increase) than in IBN group (3.4%) at 18 months. Total hip (H)-BMD significantly increased from 6 months in IBN/ALF group and tended to improve in IBN group. H-BMD was significantly higher in IBN/ALF group (4.8%) than in IBN group (3.2%) at 18 months. In conclusion, treatment with ALF in combination with IBN improves BMD in post-menopausal women with osteoporosis.
[Mh] Termos MeSH primário: Conservadores da Densidade Óssea/uso terapêutico
Densidade Óssea/efeitos dos fármacos
Difosfonatos/uso terapêutico
Hidroxicolecalciferóis/uso terapêutico
Osteoporose/tratamento farmacológico
[Mh] Termos MeSH secundário: Absorciometria de Fóton
Administração Intravenosa
Administração Oral
Idoso
Grupo com Ancestrais do Continente Asiático
Sinergismo Farmacológico
Feminino
Quadril/diagnóstico por imagem
Seres Humanos
Hidroxicolecalciferóis/efeitos adversos
Pós-Menopausa
Fosfatase Ácida Resistente a Tartarato/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bone Density Conservation Agents); 0 (Diphosphonates); 0 (Hydroxycholecalciferols); EC 3.1.3.2 (Tartrate-Resistant Acid Phosphatase); UMD7G2653W (ibandronic acid); URQ2517572 (alfacalcidol)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1620/tjem.241.319


  6 / 38262 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465598
[Au] Autor:Dong Y; Zhao R; Wang C; Guo T
[Ad] Endereço:First Affiliated Hospital of Unnan University of Traditional Chinese Medicine/Yunnan Province Hospital of Traditional Chinese Medicine.
[Ti] Título:Tuina for osteoporosis: A systematic review protocol.
[So] Source:Medicine (Baltimore);97(8):e9974, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Osteoporosis is one kind of commonly and frequently occurring global disease accompanying with serious complications. As a branch of the subject of Acupuncture-Tuina, tuina is widely applied for osteoporosis alone or combined with other methods in China and other nations while its effective evidence is not clear. Hence, this systematic review protocol purpose is to evaluate the value of its efficacy and safety for osteoporosis. METHODS: This systematic review and meta-analysis will be performed by means of electronic databases including Cochrane Library, Medline, Cochrane Library, Web of Science, EBASE, Springer, WHO International Clinical Trials Registry Platform (ICTRP), China National Knowledge Infrastructure (CNKI), Wanfang database, Chinese Biomedical Literature Database (CBM), Chinese Scientific Journal Database (VIP) and others with valid search strategy probably. The assessment of bias risk, data synthesis, subgroup analysis, and meta-analyses will be conducted using RevMan V.5.3.5 software. RESULTS: This systematic review will present a high-quality evidence for clinicians and might be the first to evaluate the efficacy and safety of tuina for osteoporosis including alleviation of pain, adverse event, spinal motor function improvement as well as improvement of self-care ability and daily living. CONCLUSION: This protocol will determine whether or not tuina is an effective and safety intervention for osteoporosis.
[Mh] Termos MeSH primário: Terapia por Acupuntura/métodos
Medicina Tradicional Chinesa/métodos
Osteoporose/terapia
[Mh] Termos MeSH secundário: Protocolos Clínicos
Seres Humanos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009974


  7 / 38262 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29348072
[Au] Autor:Liu C; Chen X; Zhi X; Weng W; Li Q; Li X; Zou Y; Su J; Hu HG
[Ad] Endereço:Department of Organic Chemistry, College of Pharmacy, Second Military Medical University, Shanghai 200433, China.
[Ti] Título:Structure-based development of an osteoprotegerin-like glycopeptide that blocks RANKL/RANK interactions and reduces ovariectomy-induced bone loss in mice.
[So] Source:Eur J Med Chem;145:661-672, 2018 Feb 10.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Osteoporosis is a metabolic bone disease characterized by low bone mass and micro-architectural deterioration of bone, for which the underlying mechanism is an imbalance between bone resorption and bone remodeling. The protein-protein interactions between receptor activator of nuclear factor-κB ligand (RANKL), RANK (its receptor), and osteoprotegerin (OPG), are known to mediate the development and activation of osteoclasts in bone remodeling, and are regarded as a pivotal therapeutic target for the treatment of osteoporosis. Herein, we disclose the successful development of a novel glycopeptide (OM-2), the structure of which is based on the key interacting sites of the reported RANKL and OPG crystal structure. OM-2 exhibited potent binding affinity with RANKL and resistance to degradation by protease enzymes. It also blocked RANKL/RANK interactions, and inhibited osteoclastogenesis in vitro. In vivo studies confirmed that OM-2 could effectively reduce bone loss and inhibit osteoclast activation in ovariectomized (OVX) mice at a dosage of 20.0 mg/kg/day. Accordingly, OM-2 is suggested as a therapeutic candidate for postmenopausal osteoporosis (PMOP) and osteoclastogenesis-related diseases like rheumatoid arthritis (RA). More importantly, its identification validates our structure-based strategy for the development of drugs that target the RANKL/RANK/OPG system.
[Mh] Termos MeSH primário: Glicopeptídeos/farmacologia
Osteoporose/tratamento farmacológico
Osteoprotegerina/farmacologia
Ovariectomia
Ligante RANK/antagonistas & inibidores
Receptores Citoplasmáticos e Nucleares/antagonistas & inibidores
[Mh] Termos MeSH secundário: Animais
Osso e Ossos/efeitos dos fármacos
Osso e Ossos/metabolismo
Osso e Ossos/patologia
Relação Dose-Resposta a Droga
Feminino
Glicopeptídeos/síntese química
Glicopeptídeos/química
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Simulação de Acoplamento Molecular
Estrutura Molecular
Osteoporose/metabolismo
Osteoprotegerina/química
Ligação Proteica/efeitos dos fármacos
Ligante RANK/metabolismo
Receptores Citoplasmáticos e Nucleares/metabolismo
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glycopeptides); 0 (Osteoprotegerin); 0 (RANK Ligand); 0 (Receptors, Cytoplasmic and Nuclear)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180120
[St] Status:MEDLINE


  8 / 38262 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29441931
[Au] Autor:Li N; Tu Y; Shen Y; Qin Y; Lei C; Liu X
[Ti] Título:Calycosin attenuates osteoporosis and regulates the expression of OPG/RANKL in ovariectomized rats MAPK signaling.
[So] Source:Pharmazie;71(10):607-612, 2016 Oct 01.
[Is] ISSN:0031-7144
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:We aimed at exploring the effect of calycosin (CA) on osteoporosis in ovariectomized (OVX) rats. Sprague-Dawley (SD) rats were divided into five groups: Sham group, OVX group, OVX group treated with estradiol valerate (EV), CAL group treated with 15 mg/kg/d of CA and CAH group treated with 30 mg/kg/d of CA for 12 weeks. Bone mineral density (BMD), histopathology, body weight, parameters in serum and urine were observed. Gene expression and protein level of OPG/RANKL were also studied by real-time PCR and western blot, respectively. We further identified the effect of CA on mitogen-activated protein kinase (MAPK) signaling. In comparison with OVX rats, CAL and CAH significantly increased the BMD by 8.3% and 19.0%. Treatment with CA notably inhibited the excretion of Ca, P and Cr. CAH also significantly increased the level of alkaline phosphatase (ALP) and decreased the level of tartrate-resistant acid phosphatase (TRAP) in serum of OVX rats. CA could improve the trabecular bone area, and increased the trabecular number and the trabecular connection after 12-week. CA also increased the expression of osteoprotegerin (OPG) and decreased the Receptor Activator for Nuclear Factor-κB Ligand (RANKL) mRNA expression compared with the OVX rats. In addition, CA could effectively decrease the phosphorylation of MAPKs induced by ovariectomy. In conclusion, CA had remarkable antiosteoporotic activity and therefore can be a promising candidate for the treatment of postmenopausal osteoporosis.
[Mh] Termos MeSH primário: Conservadores da Densidade Óssea/uso terapêutico
Isoflavonas/uso terapêutico
Proteínas Quinases Ativadas por Mitógeno/efeitos dos fármacos
Osteoporose/tratamento farmacológico
Osteoprotegerina/genética
Ligante RANK/genética
Transdução de Sinais/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Densidade Óssea/efeitos dos fármacos
Conservadores da Densidade Óssea/farmacologia
Reabsorção Óssea/prevenção & controle
Feminino
Regulação da Expressão Gênica/efeitos dos fármacos
Proteínas de Choque Térmico HSP90/biossíntese
Proteínas de Choque Térmico HSP90/genética
Isoflavonas/farmacologia
Sistema de Sinalização das MAP Quinases/efeitos dos fármacos
Osteoporose/genética
Osteoprotegerina/biossíntese
Ovariectomia
Fosforilação
Ligante RANK/biossíntese
Ratos
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bone Density Conservation Agents); 0 (HSP90 Heat-Shock Proteins); 0 (Isoflavones); 0 (Osteoprotegerin); 0 (RANK Ligand); 0 (TRAP1 protein, rat); 0 (Tnfrsf11b protein, rat); 09N3E8P7TA (7,3'-dihydroxy-4'-methoxyisoflavone); EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1691/ph.2016.6627


  9 / 38262 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29324343
[Au] Autor:Capilla AS; Soucek R; Grau L; Romero M; Rubio-Martínez J; Caignard DH; Pujol MD
[Ad] Endereço:Laboratori de Química Farmacèutica (Unitat associada al CSIC), Facultat de Farmàcia, Universitat de Barcelona, Spain.
[Ti] Título:Substituted tetrahydroisoquinolines: synthesis, characterization, antitumor activity and other biological properties.
[So] Source:Eur J Med Chem;145:51-63, 2018 Feb 10.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:This work deals with the molecular design, synthesis and biological activity of a series of tetrahydro[1,4]dioxanisoquinolines and dimethoxyisoquinoline analogues. This study describes the synthesis strategy of these potential antitumor compounds, their multi-step synthesis and their optimization. A series of tetrahydroisoquinolines was synthesized and their cytotoxicity evaluated. Some of these tetrahydroisoquinolines showed promising KRas inhibition, antiangiogenesis activity and antiosteoporosis properties. Molecular modeling studies showed that compound 12 bind in the p1 pocket of the KRas protein making interactions with the hydrophobic residues Leu56, Tyr64, Tyr71 and Thr74 and hydrogen bonds with residues Glu37 and Asp38.
[Mh] Termos MeSH primário: Inibidores da Angiogênese/farmacologia
Antineoplásicos/farmacologia
Osteoporose/tratamento farmacológico
Inibidores de Proteínas Quinases/farmacologia
Proteínas Proto-Oncogênicas p21(ras)/antagonistas & inibidores
Tetra-Hidroisoquinolinas/farmacologia
[Mh] Termos MeSH secundário: Inibidores da Angiogênese/síntese química
Inibidores da Angiogênese/química
Animais
Antineoplásicos/síntese química
Antineoplásicos/química
Ciclo Celular/efeitos dos fármacos
Linhagem Celular Tumoral
Proliferação Celular/efeitos dos fármacos
Relação Dose-Resposta a Droga
Ensaios de Seleção de Medicamentos Antitumorais
Camundongos
Modelos Moleculares
Estrutura Molecular
Inibidores de Proteínas Quinases/síntese química
Inibidores de Proteínas Quinases/química
Proteínas Proto-Oncogênicas p21(ras)/metabolismo
Relação Estrutura-Atividade
Tetra-Hidroisoquinolinas/síntese química
Tetra-Hidroisoquinolinas/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiogenesis Inhibitors); 0 (Antineoplastic Agents); 0 (KRAS protein, human); 0 (Protein Kinase Inhibitors); 0 (Tetrahydroisoquinolines); EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE


  10 / 38262 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28459066
[Au] Autor:Jang SP; Yeo I; So SY; Kim K; Moon YW; Park YS; Lim SJ
[Ad] Endereço:Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
[Ti] Título:Atypical Femoral Shaft Fractures in Female Bisphosphonate Users Were Associated with an Increased Anterolateral Femoral Bow and a Thicker Lateral Cortex: A Case-Control Study.
[So] Source:Biomed Res Int;2017:5932496, 2017.
[Is] ISSN:2314-6141
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The purpose of our study was to investigate the radiographic characteristics of atypical femoral shaft fractures (AFSFs) in females with a particular focus on femoral bow and cortical thickness. We performed a fracture location-, age-, gender-, and ethnicity-matched case-control study. Forty-two AFSFs in 29 patients and 22 typical osteoporotic femoral shaft fractures in 22 patients were enrolled in AFSF group and control group, respectively. With comparing demographics between two groups, radiographically measured femoral bow and cortical thicknesses of AFSF group were compared with control group. All AFSF patients were females with a mean age of 74.4 years (range, 58-85 years). All had a history of bisphosphonate (BP) use with a mean duration of 7.3 years (range 1-17 years). Femoral bow of AFSF group was significantly higher than control group on both anteroposterior (AP) and lateral radiographs after age correction. Mean femoral bow on an AP radiograph was 12.39° ± 5.38° in AFSF group and 3.97 ± 3.62° in control group ( < 0.0001). Mean femoral bow on the lateral radiograph was 15.71° ± 5.62° in AFSF group and 10.72° ± 4.61° in control group (after age correction = 0.003). And cortical thicknesses of AFSF group demonstrated marked disparity between tensile and compressive side of bowed femurs in this study. An adjusted lateral cortical thickness was 10.5 ± 1.4 mm in AFSF group and 8.1 ± 1.3 mm in control group (after age correction < 0.0001) while medial cortical thickness of AFSF group was not statistically different from control group. Correlation analysis showed that the lateral femoral bow on the AP radiograph was solely related to lateral CTI ( = 0.378, = 0.002). AFSFs in female BP users were associated with an increased anterolateral femoral bow and a thicker lateral cortex of femurs.
[Mh] Termos MeSH primário: Conservadores da Densidade Óssea
Difosfonatos
Fraturas do Fêmur/diagnóstico por imagem
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Conservadores da Densidade Óssea/efeitos adversos
Conservadores da Densidade Óssea/uso terapêutico
Estudos de Casos e Controles
Difosfonatos/efeitos adversos
Difosfonatos/uso terapêutico
Feminino
Fraturas do Fêmur/epidemiologia
Fêmur/diagnóstico por imagem
Seres Humanos
Meia-Idade
Osteoporose/tratamento farmacológico
Osteoporose/prevenção & controle
Radiografia
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bone Density Conservation Agents); 0 (Diphosphonates)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1155/2017/5932496



página 1 de 3827 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde